PHAT
NASDAQ · Pharmaceuticals
Phathom Pharmaceuticals Inc
$8.98
+0.23 (+2.63%)
Financial Highlights (FY 2026)
Revenue
184.97M
Net Income
-233,715,526
Gross Margin
87.1%
Profit Margin
-126.4%
Rev Growth
—
D/E Ratio
1.24
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 87.1% | 65.8% | 65.8% | 65.8% |
| Operating Margin | -91.4% | 37.3% | 39.2% | 42.8% |
| Profit Margin | -126.4% | 30.0% | 28.4% | 28.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 184.97M | 173.93M | 162.51M | 174.28M |
| Gross Profit | 161.09M | 114.44M | 106.93M | 114.67M |
| Operating Income | -168,991,148 | 64.83M | 63.74M | 74.56M |
| Net Income | -233,715,526 | 52.15M | 46.06M | 49.26M |
| Gross Margin | 87.1% | 65.8% | 65.8% | 65.8% |
| Operating Margin | -91.4% | 37.3% | 39.2% | 42.8% |
| Profit Margin | -126.4% | 30.0% | 28.4% | 28.3% |
| Rev Growth | — | -4.6% | -5.1% | +14.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 191.62M | 290.01M | 278.72M | 245.03M |
| Total Equity | 154.23M | 430.20M | 411.26M | 463.12M |
| D/E Ratio | 1.24 | 0.67 | 0.68 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -168,327,249 | 99.13M | 88.44M | 98.15M |
| Free Cash Flow | — | 45.89M | 35.44M | 36.11M |